Quarter 2 of Fiscal Year 2024:
- The equipment book-to-bill ratio stands at a commendable 1.08.
- Comparable revenue growth is at 3.0%, excluding rapid COVID-19 antigen tests, showing a strong performance compared to the previous year’s quarter (which had a growth of 11.7%).
- Imaging revenue growth is at 2.6%, with an adjusted EBIT margin of 20.2%.
- Diagnostics revenue growth is at 3.7%, excluding rapid COVID-19 antigen tests at 4.1%, with an adjusted EBIT margin of 4.1%, significantly higher than the previous year.
- Varian revenue experiences a slight decline of 2.1% compared to the exceptional growth of 27% in the prior-year quarter, yet there’s a clear enhancement in the adjusted EBIT margin to 16.4%.
- Advanced Therapies see a notable growth of 8.0% against strong growth in the previous year, with an adjusted EBIT margin of 16.2%.
- Overall adjusted EBIT margin stands at 15.1%.
- Adjusted basic earnings per share are at €0.55.
Outlook for Fiscal Year 2024:
- Siemens Healthiness confirms the expectation of comparable revenue growth between 4.5% and 6.5% (excluding revenue from rapid COVID-19 antigen tests, between 5.0% and 7.0%) and adjusted basic earnings per share between €2.10 and €2.30.
Bernd Montag, CEO of Siemens Healthiness AG, states: “The Healthineers team has continued its successful growth trajectory, even relative to an excellent prior-year quarter. After an overall strong first half of the year, we are once again well on our way to achieving our targets for the financial year.
